The Annals Visit the journal of Pharmacy Technology for more pharmacy practice research and reviews!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 25 October 2005, www.theannals.com, DOI 10.1345/aph.1G077.
 The Annals of Pharmacotherapy: Vol. 39, No. 12, pp. 2038-2044. DOI 10.1345/aph.1G077
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charpentier, M. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charpentier, M. M

NEW DRUG DEVELOPMENTS

Efaproxiral: A Radiation Enhancer Used in Brain Metastases from Breast Cancer

Margaret M Charpentier, PharmD1

1 Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 144 Fogarty Hall, Kingston, RI 02881-0809, fax 401/874-2717, chaps{at}uri.edu

Reprints: Dr. Charpentier

OBJECTIVE: To review the mechanism of action and clinical data of efaproxiral use in brain metastases of breast cancer.

DATA SOURCES: Articles were identified through MEDLINE (1966-June 2005) and EMBASE (1980-May 2005) searches using the key words efaproxiral and RSR13. Published abstracts over the previous 10 years from various scientific meetings, including American Society of Clinical Oncology and San Antonio Breast Cancer Symposium, were also searched for investigations of efaproxiral. Data on efaproxiral were also provided by Allos Therapeutics.

STUDY SELECTION AND DATA EXTRACTION: All published clinical data in humans regarding efaproxiral use in brain metastases from breast cancer were selected for this review. In addition, published studies in humans that discussed the pharmacokinetics, pharmacodynamics, and safety of efaproxiral were evaluated.

DATA SYNTHESIS: Efaproxiral is a synthetic allosteric modifier of hemoglobin that results in a shift of the hemoglobin oxygen dissociation curve to the right. Therefore, oxygen is more readily released from hemoglobin into tissues. Efaproxiral demonstrated a significant survival benefit when used as a radiation enhancer in patients with brain metastases originating from breast cancer. The safety profile of efaproxiral and improved survival rates make this agent advantageous over radiation alone. Further investigation and results from the ongoing clinical trials will help to define the role of efaproxiral in clinical practice.

CONCLUSIONS: Efaproxiral is the first synthetic allosteric modifier to demonstrate significant improvement in survival in patients undergoing radiation therapy for brain metastases of breast cancer. Validation of this effect in ongoing clinical trials will be important in determining the role of efaproxiral in brain metastases from breast cancer.

Key Words: brain metastases, breast cancer, efaproxiral

Published Online, October 25, 2005. www.theannals.com, DOI 10.1345/aph.1G077




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.